{"title":"The promise of future treatments in AF: is it all over for warfarin?","authors":"Sotiris Antoniou BPharm (Hons), MSc, DipMgt","doi":"10.1002/fps.64","DOIUrl":null,"url":null,"abstract":"<p>Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 2","pages":"6-10"},"PeriodicalIF":0.0000,"publicationDate":"2010-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.64","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.64","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd.
心房颤动的未来治疗前景:华法林是否已经结束?
阿司匹林和华法林是目前心房颤动患者中风风险的唯一治疗选择。新的口服直接凝血酶抑制剂可能提供额外的选择或可行的替代方案。在这里，我们考虑它们的潜在作用，重点是达比加群。版权所有©2010 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
